Please use this identifier to cite or link to this item: http://10.1.7.192:80/jspui/handle/123456789/6117
Full metadata record
DC FieldValueLanguage
dc.contributor.authorJaviya, V. A.-
dc.contributor.authorPatel, J. A.-
dc.date.accessioned2015-09-04T10:59:08Z-
dc.date.available2015-09-04T10:59:08Z-
dc.date.issued2006-
dc.identifier.urihttp://hdl.handle.net/123456789/6117-
dc.descriptionIndian Journal of Pharmacology, 38(4); 2006en_US
dc.description.abstractIncreasing attention has been focused on the role of peroxisome proliferator-activated receptors (PPARs) in the past decade. Compelling data have begun to unite work from various arenas, such as epidemiology and vascular biology. Clinical trials with synthetic PPAR agonists have exhibited therapeutic benefits in treating various chronic diseases like atherosclerosis, diabetes mellitus and cardiovascular diseases. The PPARs, a family of nuclear receptors (NRs), are a set of three receptor sub-types encoded by distinct genes. They function as lipid sensors to regulate a broad range of genes in many metabolically active tissues. The discovery of PPAR-specific ligands has led to a significant advancement in our understanding of the structure of these receptor proteins and molecular mechanisms of their ligand dependent activation. Herein, we have tried to delineate the role of PPARs as molecular targets for the development of new drugs to treat human metabolic diseases.en_US
dc.publisherIndian Pharmacological Societyen_US
dc.relation.ispartofseriesIPFP0180;-
dc.subjectPPARsen_US
dc.subjectPPAR ligandsen_US
dc.subjectNuclear hormone receptor,en_US
dc.subjectMetabolic diseasesen_US
dc.subjectIPFP0180en_US
dc.titleThe Role of Peroxisome Proliferator-Activated Receptors in Human Diseaseen_US
dc.typeFaculty Papersen_US
Appears in Collections:Faculty Papers

Files in This Item:
File Description SizeFormat 
IPFP0180.pdfIPFP0180310.42 kBAdobe PDFThumbnail
View/Open


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.